Moolec Science S.A.(MLEC)Earnings, Financials & Key Ratios
MLEC•NASDAQ
Price updated Jun 19, 2026
AboutMoolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.Show more
- Revenue$334M+5830.7%
- EBITDA$12M+246.7%
- Net Income-$111M-1424.3%
- EPS (Diluted)-258.75-8978.9%
- Gross Margin34.17%+306.8%
- EBITDA Margin3.53%+102.5%
- Operating Margin-3.14%+98.0%
- Net Margin-33.41%+74.3%
MLEC Key Insights
Moolec Science S.A. (MLEC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Share count reduced 83.2% through buybacks
- ✓Efficient asset utilization: 1.6x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MLEC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MLEC Price & Volume
Moolec Science S.A. (MLEC) stock price & volume — 10-year historical chart
Loading chart...
MLEC Growth Metrics
Moolec Science S.A. (MLEC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM170.36%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-27.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-27.02%
Return on Capital
10 Years-32.13%
5 Years-32.13%
3 Years-52.72%
Last Year-8.76%
MLEC Peer Comparison
Moolec Science S.A. (MLEC) competitors in Life Science Tools and Reagents — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RKDA | 1.2M | 0.78 | -0.45 | -3.71% | -195.94% | -219.35% | ||
 PGEN | 1.45B | 4.82 | -3.42 | 146.73% | -6.47% | -17.69% | 0.24 | |
 SLP | 367.47M | 18.24 | -5.66 | 13.09% | -81.66% | -50.54% | 0.00 | |
 BYND | 329.55M | 0.71 | -0.39 | -15.61% | 92.22% | |||
 SMPL | 1.26B | 12.63 | 12.38 | 8.98% | 6.26% | 5.23% | 0.17 | |
 ADM | 36.19B | 75.10 | 33.68 | -6.15% | 1.34% | 4.72% | 0.37 | |
 BG | 21.84B | 112.58 | 22.88 | 32.42% | 0.85% | 4.28% | 0.97 | |
 CTVA | 52.74B | 78.56 | 49.10 | 2.92% | 6.5% | 4.62% | 0.11 |
Compare MLEC vs Peers
Moolec Science S.A. (MLEC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MLEC Income Statement
Moolec Science S.A. (MLEC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 905.05K | 5.63M | 333.61M | 7.83M |
Revenue Growth % | - | - | - | 521.53% | 5830.74% | 170.36% |
Cost of Goods Sold | 0 | 0 | 1.05M | 5.15M | 219.61M | 8.47M |
COGS % of Revenue | - | - | 115.83% | 91.6% | 65.83% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -143.31K▲ 0% | 472.58K▲ 429.8% | 114.01M▲ 24024.0% | -639.5K▲ 0% |
Gross Margin % | - | - | -15.83% | 8.4% | 34.17% | -8.16% |
Gross Profit Growth % | - | - | - | 429.77% | 24023.99% | - |
Operating Expenses | 13.8K | 3.65M | 6.51M | 9.52M | 124.48M | 8.5M |
OpEx % of Revenue | - | - | 719.35% | 169.16% | 37.31% | - |
Selling, General & Admin | 13.8K | 2.63M | 47.67M | 7.18M | 115.25M | 6.35M |
SG&A % of Revenue | - | - | 5267.37% | 127.62% | 34.55% | - |
Research & Development | 0 | 985.16K | 1.35M | 1.77M | 9.24M | 1.59M |
R&D % of Revenue | - | - | 149.11% | 31.51% | 2.77% | - |
Other Operating Expenses | 0 | 38.98K | -42.51M | 564.22K | 0 | 562.09K |
Operating Income | -13.8K▲ 0% | -1.72M▼ 12339.6% | -6.65M▼ 287.6% | -9.04M▼ 35.9% | -10.48M▼ 15.9% | -9.14M▲ 0% |
Operating Margin % | - | - | -735.19% | -160.76% | -3.14% | -116.72% |
Operating Income Growth % | - | -12339.56% | -287.6% | -35.91% | -15.87% | - |
EBITDA | 192.5K | -1.71M | -6.53M | -8.03M | 11.78M | -7.95M |
EBITDA Margin % | - | - | -721.7% | -142.73% | 3.53% | -101.45% |
EBITDA Growth % | - | -990.9% | -280.87% | -22.92% | 246.66% | -69.74% |
D&A (Non-Cash Add-back) | 206.3K | 1.7K | 122.02K | 1.01M | 22.25M | 1.2M |
EBIT | -13.8K | -3.65M | -51.86M | -7.19M | -91.27M | -6.41M |
Net Interest Income | 0 | 11.19K | 532.99K | 773.43K | -40.87M | -495.11K |
Interest Income | 0 | 13.32K | 693.03K | 1.94M | 944.19K | 1.69M |
Interest Expense | 0 | 2.13K | 160.03K | 1.17M | 41.81M | 2.18M |
Other Income/Expense | 0 | 1.62M | -45.37M | 703.55K | -159.53M | 519.5K |
Pretax Income | -13.8K▲ 0% | -93.81K▼ 579.7% | -52.02M▼ 55357.3% | -8.34M▲ 84.0% | -170M▼ 1938.6% | -8.62M▲ 0% |
Pretax Margin % | - | - | -5748.13% | -148.25% | -50.96% | -110.09% |
Income Tax | 0 | 0 | -234.54K | -1.05M | 6.64M | -342.8K |
Effective Tax Rate % | 0% | 0% | 0.45% | 12.55% | -3.9% | 3.98% |
Net Income | -13.8K▲ 0% | -4.53M▼ 32698.9% | -51.79M▼ 1044.0% | -7.31M▲ 85.9% | -111.46M▼ 1424.3% | -8.28M▲ 0% |
Net Margin % | - | - | -5722.22% | -129.99% | -33.41% | -105.71% |
Net Income Growth % | - | -32698.91% | -1044.02% | 85.88% | -1424.3% | -27.76% |
Net Income (Continuing) | -13.8K | -93.81K | -51.79M | -7.29M | -176.64M | -8.28M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | -16.9M | 0 |
EPS (Diluted) | -0.01▲ 0% | -1.80▼ 14900.0% | -22.50▼ 1150.0% | -2.85▲ 87.3% | -258.75▼ 8978.9% | -3.19▲ 0% |
EPS Growth % | - | -14900% | -1150% | 87.33% | -8978.95% | -27.02% |
EPS (Basic) | -0.01 | -1.80 | -22.50 | -2.85 | -258.75 | - |
Diluted Shares Outstanding | 1.16M | 2.5M | 2.3M | 2.57M | 430.86K | 2.6M |
Basic Shares Outstanding | 1.16M | 2.5M | 2.3M | 2.57M | 430.86K | 2.6M |
Dividend Payout Ratio | - | - | - | - | - | - |
MLEC Balance Sheet
Moolec Science S.A. (MLEC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 581.7K | 1.08M | 5.33M | 13.75M | 31.19M | 9.54M |
Cash & Short-Term Investments | 337.6K | 1.08M | 2.83M | 5.39M | 9.02M | 1.93M |
Cash Only | 337.6K | 1.08M | 2.53M | 5.39M | 767.92K | 1.93M |
Short-Term Investments | 0 | 0 | 306.03K | 0 | 8.25M | 0 |
Accounts Receivable | 0 | 0 | 1.69M | 1.48M | 19.92M | 2.74M |
Days Sales Outstanding | - | - | 682.08 | 96.17 | 21.8 | 88.34 |
Inventory | 0 | 0 | 465.75K | 6.28M | 2.24M | 4.84M |
Days Inventory Outstanding | - | - | 162.16 | 444.83 | 3.72 | 184.05 |
Other Current Assets | 244.09K | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 138.01M | 4.61M | 18.72M | 21.04M | 173.52M | 21.84M |
Property, Plant & Equipment | 0 | 8.92K | 1.19M | 1.62M | 3.45M | 1.63M |
Fixed Asset Turnover | - | - | 0.76x | 3.48x | 96.81x | 4.86x |
Goodwill | 0 | 0 | 251.44K | 262.53K | 0 | 281.03K |
Intangible Assets | 0 | 4.6M | 8.52M | 8.98M | 75.26M | 9.06M |
Long-Term Investments | 138.01M | 138.01M | 8.76M | 10.15M | 94.81M | 41.29M |
Other Non-Current Assets | 0 | -138.01M | 0 | 36.02K | 0 | 25.45K |
Total Assets | 138.59M▲ 0% | 5.69M▼ 95.9% | 24.05M▲ 322.6% | 34.79M▲ 44.6% | 204.71M▲ 488.5% | 31.38M▲ 0% |
Asset Turnover | - | - | 0.04x | 0.16x | 1.63x | 0.25x |
Asset Growth % | - | -95.89% | 322.57% | 44.64% | 488.47% | 166.44% |
Total Current Liabilities | 861.85K | 4.09M | 12.6M | 8.15M | 236.05M | 6.46M |
Accounts Payable | 0 | 164.13K | 2.34M | 873.53K | 6.49M | 1.03M |
Days Payables Outstanding | - | - | 814.39 | 61.88 | 10.79 | 35.31 |
Short-Term Debt | 125K | 125K | 2.55M | 2.56M | 227.27M | 2.37M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 1.26K | 0 |
Other Current Liabilities | 736.85K | 2.74M | 1.65M | 789.87K | 2.05M | 486.69K |
Current Ratio | 0.67x | 0.27x | 0.42x | 1.69x | 0.13x | 1.48x |
Quick Ratio | 0.67x | 0.27x | 0.39x | 0.92x | 0.12x | 0.73x |
Cash Conversion Cycle | - | - | 29.85 | 479.12 | 14.72 | 237.07 |
Total Non-Current Liabilities | 3.64M | 2.2M | 1.35M | 19.82M | 51.53M | 22.13M |
Long-Term Debt | 0 | 0 | 99.05K | 11.7M | 19.61M | 19.37M |
Capital Lease Obligations | 0 | 0 | 0 | 248.53K | 0 | 910.68K |
Deferred Tax Liabilities | 0 | 0 | 1.07M | 72.1K | 15.77M | 1.02M |
Other Non-Current Liabilities | 3.64M | 2.2M | 175.31K | 7.8M | 16.15M | 2.27M |
Total Liabilities | 4.51M | 4.09M | 13.95M | 27.97M | 287.58M | 28.58M |
Total Debt | 125K | 125K | 2.65M | 14.68M | 246.88M | 22.09M |
Net Debt | -212.6K | -956.81K | 117.62K | 9.29M | 246.11M | 20.16M |
Debt / Equity | 0.00x | 0.08x | 0.26x | 2.15x | - | 7.90x |
Debt / EBITDA | 0.65x | - | - | - | 20.97x | -2.78x |
Net Debt / EBITDA | -1.10x | - | - | - | 20.90x | -2.54x |
Interest Coverage | - | -805.94x | -41.58x | -7.76x | -0.25x | -2.94x |
Total Equity | 134.08M▲ 0% | 1.6M▼ 98.8% | 10.11M▲ 529.9% | 6.82M▼ 32.6% | -82.87M▼ 1315.9% | 2.8M▲ 0% |
Equity Growth % | - | -98.8% | 529.91% | -32.56% | -1315.91% | -169.4% |
Book Value per Share | 115.79 | 0.64 | 4.40 | 2.66 | -192.34 | 1.08 |
Total Shareholders' Equity | 134.08M | 1.6M | 10.11M | 6.82M | -65.97M | 2.8M |
Common Stock | 129.08M | 638.3K | 375.64K | 385.64K | 1.09M | 401.27K |
Retained Earnings | -828.08K | -6.83M | -58.62M | -65.94M | -110.32M | -70.28M |
Treasury Stock | - | 0 | 0 | -305K | -422.15K | -305K |
Accumulated OCI | 0 | 0 | 18.11K | 125.71K | 3.93M | 786.33K |
Minority Interest | 0 | 0 | 0 | 0 | -16.9M | 0 |
MLEC Cash Flow Statement
Moolec Science S.A. (MLEC) cash flow — operating, investing & free cash flow history
| Metric | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -8.8K | -915.08K | -7.51M | -9.33M | -24.45M | -5.7M |
Operating CF Margin % | - | - | -829.94% | -165.83% | -7.33% | - |
Operating CF Growth % | - | -10296.3% | -720.84% | -24.19% | -162.13% | 212.51% |
Net Income | -13.8K | -4.53M | -51.79M | -7.31M | -111.46M | -8.28M |
Depreciation & Amortization | 0 | 1.7K | 122.02K | 1.01M | 22.25M | 1.2M |
Stock-Based Compensation | 0 | 838.58K | 43.8M | 2.05M | 0 | 866.66K |
Deferred Taxes | 0 | 860K | -234.54K | -1.05M | 6.64M | -342.8K |
Other Non-Cash Items | 0 | 985.37K | -1.14M | -983.96K | 15.23M | -920.49K |
Working Capital Changes | 5K | 926.18K | 1.73M | -3.05M | 42.89M | 1.78M |
Change in Receivables | 0 | 0 | -44.13K | 273.09K | 28.08M | -823.18K |
Change in Inventory | 0 | 0 | 66.48K | -5.79M | 34.88M | -3.72M |
Change in Payables | 0 | 926.71K | 1.49M | 2.5M | -18.85M | 6.24M |
Cash from Investing | 0 | -138M | -2.34M | 134.87K | -35.99M | -270.17K |
Capital Expenditures | 0 | 0 | -179.19K | -158.28K | -6M | -177.23K |
CapEx % of Revenue | - | - | 19.8% | 2.81% | 1.8% | 2.26% |
Acquisitions | 0 | 0 | -1.93M | 0 | -31.75M | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -8.61M | -242.73K |
Cash from Financing | 14.49K | 139.05M | 11.28M | 11.71M | 13.07M | 5.95M |
Debt Issued (Net) | 295K | 0 | 1.3M | 10.91M | 23.3M | 4.79M |
Equity Issued (Net) | 26.2K | 1000K | 1000K | 1000K | -926.9K | 764.6K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -305K | -926.9K | -305K |
Other Financing | -306.71K | -403.89K | -24.1K | -1.38M | -9.3M | -1.04M |
Net Change in Cash | 5.69K▲ 0% | 131.02K▲ 2203.1% | 1.45M▲ 1003.5% | 2.86M▲ 98.0% | -52.23M▼ 1924.7% | 228.43K▲ 0% |
Free Cash Flow | -8.8K▲ 0% | -1.89M▼ 21326.7% | -7.69M▼ 307.8% | -9.49M▼ 23.4% | -30.1M▼ 217.3% | -6.12M▲ 0% |
FCF Margin % | - | - | -849.74% | -168.65% | -9.02% | -78.09% |
FCF Growth % | - | -21326.71% | -307.77% | -23.35% | -217.33% | 52.73% |
FCF per Share | -0.01 | -0.75 | -3.35 | -3.70 | -69.87 | -2.36 |
FCF Conversion (FCF/Net Income) | 0.64x | 0.20x | 0.15x | 1.28x | 0.22x | 0.74x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
MLEC Key Ratios
Moolec Science S.A. (MLEC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | -6.67% | -884.5% | -86.42% | - | -150.93% |
Return on Invested Capital (ROIC) | -1.91% | -91.81% | -51.52% | -8.76% | -34.5% |
Gross Margin | - | -15.83% | 8.4% | 34.17% | -8.16% |
Net Margin | - | -5722.22% | -129.99% | -33.41% | -105.71% |
Debt / Equity | 0.08x | 0.26x | 2.15x | - | 7.90x |
Interest Coverage | -805.94x | -41.58x | -7.76x | -0.25x | -2.94x |
FCF Conversion | 0.20x | 0.15x | 1.28x | 0.22x | 0.74x |
Revenue Growth | - | - | 521.53% | 5830.74% | 170.36% |
Related:MLEC Dividend History·MLEC Revenue History·MLEC Price History·MLEC P/E History·MLEC Financial Ratios·MLEC Institutional Holders
MLEC Frequently Asked Questions
Moolec Science S.A. (MLEC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Moolec Science S.A. (MLEC) reported $7.8M in revenue for fiscal year 2024.
Moolec Science S.A. (MLEC) grew revenue by 5830.7% over the past year. This is strong growth.
Moolec Science S.A. (MLEC) reported a net loss of $8.3M for fiscal year 2024.
Dividend & Returns
Moolec Science S.A. (MLEC) had negative free cash flow of $6.1M in fiscal year 2024, likely due to heavy capital investments.